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The impact of neuroinflammation and microglial activation to Parkinson’s disease
(PD) progression is still debated. Post-mortem analysis of PD brains has shown
that neuroinflammation and microgliosis are key features of end-stage disease.
However, microglia neuroimaging studies and evaluation of cerebrospinal fluid
(CSF) cytokines in PD patients at earlier stages do not support the occurrence
of a pronounced neuroinflammatory process. PD animal models recapitulating
the motor and non-motor features of the disease, and the slow and progressive
neuropathology, can be of great advantage in understanding whether and how
neuroinflammation associates with the onset of symptoms and neuronal loss. We
recently described that 18-month-old NF-κB/c-Rel deficient mice (c-rel−/−) develop a
spontaneous late-onset PD-like phenotype encompassing L-DOPA-responsive motor
impairment, nigrostriatal neuron degeneration, α-synuclein and iron accumulation.
To assess whether inflammation and microglial activation accompany the onset and
the progression of PD-like pathology, we investigated the expression of cytokines
(interleukin 1 beta (Il1b), interleukin 6 (Il6)) and microglial/macrophage activation
markers (Fc gamma receptor III (Fcgr3), mannose receptor 1 (Mrc1), chitinase-like 3
(Ym1), arginase 1 (Arg 1), triggering receptor expressed on myeloid cells 2 (Trem2)),
together with microglial ionized calcium binding adapter molecule 1 (Iba1) and astrocyte
glial fibrillary acidic protein (GFAP) immunolabeling, in the substantia nigra (SN) of
c-rel−/− mice, at premotor (4- and 13-month-old) and motor phases (18-month-old). By
quantitative real-time RT-PCR we found increased M2c microglial/macrophage markers
expression (Mrc1 and Arg1) in 4-month-old c-rel−/− mice. M2-type transcription
dropped down in 13-month-old c-rel−/− mice. At this age, the pro-inflammatory
Il1b, but not Il6 or the microglia-macrophage M1-polarization marker Fcgr3/CD16,
increased when compared to wild-type (wt). Furthermore, no significant variation
in the transcription of inflammatory and microglial/macrophage activation genes
was present in 18-month-old c-rel−/− mice, that display motor dysfunctions and
dopaminergic neuronal loss. Immunofluorescence analysis of Iba1-positive cells in the
Abbreviations: Arg1, arginase 1; CNS, central nervous system; CSF, cerebrospinal fluid; DAT, dopamine transporter;
Fcgr3, Fc gamma receptor III, also known as CD16; GFAP, glial fibrillary acidic protein; Iba1, ionized calcium binding
adapter molecule 1; Il6, interleukin 6; Il1b, interleukin 1 beta; Mrc1, mannose receptor 1; PD, Parkinson’s disease;
qRT-PCR, real-time quantitative reverse transcription-polymerase chain reaction; SN, substantia nigra; Trem2, triggering
receptor expressed on myeloid cells 2; Ym1, chitinase-like 3.
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SN revealed no sign of overt microglial activation in c-rel−/− mice at all the time-points.
MRC1-Iba1-positive cells were identified as non-parenchymal macrophages in 4-month-
old c-rel−/− mice. Finally, no sign of astrogliosis was detected in the SN of the diverse
animal groups. In conclusion, this study supports the presence of a mild inflammatory
profile without evident signs of gliosis in c-rel−/− mice up to 18 months of age. It suggests
that symptomatic PD-like phenotype can develop in the absence of concomitant severe
inflammatory process.
Keywords: c-Rel, neuroinflammation, microglia, Parkinson’s disease, astrocytes, substantia nigra
INTRODUCTION
Parkinson’s disease (PD) is the major neurodegenerative motor
disorder worldwide, characterized by motor symptoms such
as bradykinesia, resting tremor and rigidity. Key hallmarks of
the brains of affected patients are the loss of dopaminergic
neurons of substantia nigra (SN) pars compacta and Lewy
bodies, intracellular inclusions mainly composed by aggregated
α-synuclein (Poewe et al., 2017). Although the neuropathological
features of the disease have been well described, the biological
basis of neuronal death still needs to be clarified. Nonetheless,
processes such as neuroinflammation and microglial activation
have been proposed to contribute to the onset of PD (Poewe et al.,
2017).
Microglia, the resident immune cells of the brain (Aguzzi
et al., 2013), are essential for brain homeostasis in physiological
conditions (Nimmerjahn et al., 2005; Neumann et al., 2009;
Miyamoto et al., 2013). During brain injury, microglia become
activated, which can be either detrimental or protective for
neuronal cells in the central nervous system (CNS; Hayakawa
et al., 2008; Brites and Vaz, 2014; Hu et al., 2015). The opposite
role of microglia in brain diseases has been hypothesized to arise
from the fact that these cells can adopt diverse activation states
(Tang and Le, 2016). In particular, the classification ofmonocyte-
derived macrophages into classically (M1) and alternatively
activated (M2) was later applied to microglia (Gordon, 2003).
While the M1 state has been associated with pro-inflammatory
responses (Hu et al., 2015), the alternatively activated state
M2 has been found to be related to healing and scavenging. In
addition, three different M2 sub-classes have been described:
M2a, M2b and M2c, that have been associated with tissue
repair, regulation of inflammation and tissue remodeling, and
debris and iron scavenging, respectively (David and Kroner,
2011).
The first evidence of increased microglial activation in
post-mortem brains of PD patients was published by McGeer
and collaborators almost 30 years ago (McGeer et al., 1988).
Since then, microgliosis and inflammation have been thought to
play a role in PD pathogenesis and/or progression (Long-Smith
et al., 2009). On the other hand, the relevance of astrogliosis in
PD pathology remains debated (Hirsch and Hunot, 2009), due
to contrasting results of studies in PD patients (Knott et al.,
1999; Mirza et al., 2000; Thannickal et al., 2007; Song et al.,
2009; Tong et al., 2015). Indeed, post-mortem analysis of PD
brains showed increased reactive microglia in the SN around the
surviving dopaminergic neurons, as well as an augmented level
of cytokines (McGeer et al., 1988; Mogi et al., 1994a; Banati et al.,
1998; Imamura et al., 2003), indicating a clear involvement of
microglia and inflammation at the end stage of the disease. In
order to evaluate neuroinflammation during different stages of
the disease, several studies have analyzed the content of cytokines
in the cerebrospinal fluid (CSF) of patients affected by PD, which
is considered a representative indicator of pathological brain
states. Earlier studies found an increase in the levels of cytokines,
such as interleukin 6 (IL-6), interleukin 1 beta (IL-1β), TNFα and
TGF-β, in CSF from relatively small cohorts of PD patients (Mogi
et al., 1994b, 1995, 1996; Blum-Degen et al., 1995; Vawter et al.,
1996; Müller et al., 1998). On the other hand, more recent studies
on larger patients’ cohorts showed no differences in the CSF
levels of IL-6 and TNFα (Lindqvist et al., 2013), and fractalkine
(Shi et al., 2011), in PD subjects compared to controls. Thus,
while clear neuroinflammatory pathology has been established
in the post-mortem brain of late-stage PD, it remains arguable
the participation of inflammatory processes with microglial
activation in the earlier and progressive stages of PD.
Animal models of PD could be valuable tools to investigate
whether inflammation with microglial activation, and its
diverse activation states, occurs along with SN degeneration
and the onset of motor dysfunction. However, none of
the available models fully recapitulates the pathological
hallmarks and the slow progression of PD (Cebrián et al.,
2015). Thus, the importance of these pathological features
to the onset and worsening of the disease is still an open
question.
We have previously shown that mice deficient for the NF-
κB c-Rel nuclear factor (c-rel−/− mice) develop a late-onset
parkinsonism (Baiguera et al., 2012) characterized by significant
impairment in spontaneous motor activity. They displayed an
L-DOPA-reversible hypo-motility and gait-related deficits at
18 months, but not at younger ages (Baiguera et al., 2012). The
motor deficits observed in aged c-rel−/− mice were accompanied
by a significant loss of dopaminergic neurons and accumulation
of α-synuclein aggregates in the SN, marked reduction of
dopaminergic terminals and dopamine content in the striatum,
as well as increased expression of divalent metal transporter
1 and iron staining in SN and striatum (Baiguera et al., 2012).
Furthermore, we described that the SN and striatum of 18-
month-old c-rel−/− mice displayed a significant increase in the
area of CD11b-positive microglia (Baiguera et al., 2012). More
recently, we found that c-rel−/− mice displayed progressive
accumulation of pathological α-synuclein in SN, as well as striatal
loss of dopamine transporter (DAT) as early as 12 months of
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age, when they did not show either motor impairment or loss
of dopaminergic neurons in the SN yet (Lanzillotta et al., 2015;
Parrella et al., submitted). In this premotor phase (2–13 months
of age), c-rel−/− showed non-motor symptoms typical of PD,
such as hyposmia and gastrointestinal dysfunctions (Lanzillotta
et al., 2015; Parrella et al., submitted).
In this study, we investigated whether there is a temporal
correlation between inflammatory transcription and
microglial/astrocyte activation with the development of the
spontaneous PD-like pathology in c-rel−/− mice. We evaluated
markers of inflammation and microglial/macrophage activation,
as well as signs of gliosis, in the premotor and motor stages of
c-rel−/− mice at 4, 13 and 18 months of age.
MATERIALS AND METHODS
Experimental Animals
C57BL/6 mice carrying the c-Rel gene null mutation (c-rel−/−)
were originally generated by inserting the neomycin cassette
into the fifth exon of the c-Rel gene (Liou et al., 1999). The
genotypes were confirmed by PCR analysis (Baiguera et al., 2012)
and western blot, and both lines were continued by homozygous
breeding. The c-rel−/− and c-rel+/+ wild-type (wt) mice were
housed in the animal facility of the Department of Molecular
and Translational Medicine of the University of Brescia. Animals
were maintained in standard cages under 12/12 h light/dark
cycles with ad libitum access to food and water. Humidity and
room temperature were maintained constant. This study was
carried out in accordance with the recommendations of the
Directive 2010/63/EU of the European Parliament and of the
Council of 22 September 2010 on the protection of animals used
for scientific purposes. The protocol was approved by the animal-
welfare body of the University of Brescia. Male 4-, 13- and 18-
month-old mice were used for this study.
Real-Time Quantitative Reverse
Transcription-Polymerase Chain Reaction
(qRT-PCR)
Total RNA was purified from SN using the RNeasy Mini Kit for
total RNA extractions (Qiagen). Total RNA (1 µg) was reverse
transcribed using the Quantitectr Reverse Transcription
Kit (Qiagen) according to manufacture instructions.
Retrotranscribed cDNA (1–5 µL) was amplified using iQTM
SYBR Green Supermix (Bio-Rad) and 10 µM optimized forward
and reverse primers. PCR reaction was performed using the
standard program in ViiA7TM Real-Time PCR System (Applied
Biosystems). Each reaction was performed at least in triplicate.
For standardization of quantification, beta-Actin (Actb) was
used as housekeeping gene. Data were analyzed following the
comparative Ct method. The following primers were used for
real-time quantitative reverse transcription-polymerase chain
reaction (qRT-PCR):
• arginase 1 (Arg1): For GTGTACATTGGCTTGCGAGA; Rev
AATCGGCCTTTTCTTCCTTC
• Actb: For GGCTCTTTTCCAGCCTTCCT; Rev ATGCCT
GGGTACATGGTGGT
• Fc gamma receptor III (Fcgr3): For TATCGGTG
TCAAATGGAGCA; Rev GCACCT TAGCGTGATGGTTT
• Il6: For CCTACCCCAATTTCCAATGCT; Rev TATTTT
CTGACCACAGTGAGGAAT
• Il1b: For GGCTTCAGGCAGGCAGTATC; Rev TAATGG
GAACGTCACACACC
• mannose receptor 1 (Mrc1): For AAGGTTCGGGATTGTG
GAG; Rev AATCGGCCTTTTCTTCCTTC
• triggering receptor expressed on myeloid cells 2 (Trem2):
For CACTCTGAAGAACCTCCAAGC; Rev ATTCCTGGAG
GTGCTGTGTT
• chitinase-like 3 (Ym1): For GCCCACCAGGAAAGTACACA;
Rev CACGGCACCTCCTAAATTGT
Immunofluorescence
Mice were anesthetized with chloral hydrate (400 mg/kg
intraperitoneally) and transcardially perfused with PBS (Sigma-
Aldrich) and 4% (w/v) ice-cold paraformaldehyde (PFA). Brains
were postfixed in 4% PFA at 4◦C for 2 h, followed by
cryoprotection in 30% sucrose in PBS until cut. Coronal
slices (15 µm-thick) were cut to obtain serial sections of the
SN (anterior–posterior 2.54–3.40 mm), using bregma-based
coordinates (Paxinos and Franklin, 2012).
Immunofluorescence for the ionized calcium binding adapter
molecule 1 (Iba1) and glial fibrillary acidic protein (GFAP)
antibodies was initiated by performing antigen retrieval (Tris-
EDTA Buffer pH 9, 90◦C, 10 min), followed by permeabilization
and blocking. Then, sections were incubated overnight at 4◦C
with the primary antibodies rabbit anti-Iba1 (1:500, Wako
#019-19741) or mouse anti-GFAP (1:100, Sigma #G3893).
The following day, slices were incubated for 1 h at room
temperature with the secondary antibodies goat anti-rabbit Alexa
Fluor 488 (1:1000, Jackson ImmunoResearch #111-545-144),
for Iba1, and goat anti-mouse Alexa Fluor 488 (1:800, Jackson
ImmunoResearch #115-546-071), for GFAP. Lastly, sections
were incubated with Hoechst 33342 (1 mg/mL, Sigma-Aldrich)
to stain cellular nuclei.
Double immunofluorescence staining forMRC1 and Iba1 was
initiated by performing antigen retrieval, permeabilization and
blocking, followed by an overnight incubation at 4◦C with rat
anti-mouse MRC1 (1:50, Bio-Rad #MCA2235). Sections were
then incubated for 1 h at room temperature in biotinylated
goat anti-rat (1:400, Vector laboratories #BA-9401) followed by
streptavidin-Alexa Fluor 488 (1:1000, ThermoFisher Scientific
#S11227). Then, the sections were incubated 2 h at 37◦C in the
second primary antibody rabbit anti-Iba1, goat anti-rabbit Alexa
Fluor 488, and Hoechst 33342.
Double immunofluorescence staining for IL-1β and Iba1 was
performed by incubating sections in goat anti-Iba1 (1:100, Novus
Biologicals #NB 300-270) overnight at 4◦C followed by donkey
anti-goat Alexa Fluor 488 (1:500, Jackson ImmunoResearch
#705-545-147). Slices were then incubated in the second primary
antibody rabbit anti-IL-1β (1:50, Abcam #ab9722) overnight at
4◦C, followed by biotinylated goat anti-rabbit (1:400, Vector
laboratories #BA-1000), streptavidin-Alexa Fluor 488, and lastly
Hoechst 33342. In order to check antibody specificity, control
(blank) reactions with no primary antibodies were run in parallel.
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FIGURE 1 | Inflammatory and microglial/macrophage mRNA expression profile in c-rel−/− and wild-type (wt) mice. Real-time quantitative reverse transcription-
polymerase chain reaction (qRT-PCR) analysis of pro-inflammatory cytokines, interleukin 1 beta (Il1b) and interleukin 6 (Il6; A,B), and microglial/macrophage
activation markers, Fc gamma receptor III (Fcgr3; C), for M1 phenotype; mannose receptor 1 (Mrc1; D), chitinase-like 3 (Ym1; E), arginase 1 (Arg1); (F), and
triggering receptor expressed on myeloid cells 2 (Trem2); (G), for M2 state in substantia nigra (SN) of 4, 13 and 18 months of age mice (n = 4–6 animals per group).
Four-month-old c-rel−/− mice showed increased expression of M2c microglial marker Mrc1 and Arg1, associated with marked decrease of Ym1 transcription. At
13 months of age, c-Rel deficient mice displayed an upregulation in Il1b transcription compared to younger c-rel−/− mice, while no differences in microglial
M2 markers were found in c-rel−/− mice compared to wt group. No biologically relevant variations in all the analyzed markers were evident in 18-month-old c-rel−/−
mice compared to wt. Data are presented as mean ± SEM. ∗P < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; two-way analysis of variance (ANOVA) followed by Bonferroni test
for comparison vs. 4-month-old wt mice.
Microscopy
Immunofluorescence stainings were analyzed by an inverted
light/epifluorescence microscope (Olympus IX50; Olympus),
and pictures were captured with a digital camera (Olympus
XC 30) and cellSens Software (Olympus) and analyzed in
a blinded manner. Images were adjusted for brightness
and contrast with Adobe Photoshop (Adobe system)
software.
Statistical Analysis
Statistical analysis was performed with the GraphPad Prism
program (GraphPad Software). qRT-PCR data was analyzed by
two-way analysis of variance (ANOVA) followed by Bonferroni
post hoc test. Data are presented as mean ± SEM. P < 0.05 was
considered as significant.
RESULTS
Age-Related Alterations in the Expression
of Inflammatory and
Microglial/Macrophage Activation Markers
in the Substantia Nigra of c-Rel Deficient
Mice
We first evaluated the expression of general markers
of inflammation and specific markers for the diverse
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microglial/macrophage activation states, M1 (pro-inflammatory)
and M2 (anti-inflammatory, phagocytic) by qRT-PCR on
SN RNA extracts of wt and c-rel−/− mice at 4, 13 and
18 months. In particular, we analyzed the pro-inflammatory
markers Il1b and Il6, that are widely expressed in the
CNS, and Fcgr3/CD16, that is specifically expressed
by M1-polarized microglia/macrophages. Moreover, we
determined the expression of Mrc1, Ym1, Arg1 and
Trem2, specific markers for the M2 activation state of
microglia/macrophages.
At 4 months of age, no differences were found in the mRNA
expression of the pro-inflammatory markers Il1b and Il6, and
M1 microglia/macrophage marker Fcgr3 in the SN of c-rel−/−
mice when compared to wt (Figures 1A–C). At 13 months of
age, a statistically significant increase of Il1b expression was
detected only in c-rel−/− mice (Figure 1A). This age-dependent
increase in Il1b transcription was also detected in the wt mice
at 18 months of age (Figure 1A). Interestingly, the levels of Il1b
in 18-month-old c-rel−/− mice were not significantly different
from those observed at 4 months (Figure 1A). However, no
biologically relevant, albeit statistically significant, differences in
the expression of Il6 or Fcgr3 were observed between c-rel−/−
and wt mice at all the time points analyzed (Figures 1B,C).
These analyses only showed an age-related decrease of Il6,
occurring in both mouse lines, and a statistically significant
increase of Fcgr3 in 18-month-old wt mice (Figure 1C). On
the other hand, the analysis of the expression of M2 markers
in 4-month-old mice showed a significant increase of Mrc1
and a trend to increase for Arg1 transcription in c-rel−/−
mice when compared to wt, while Ym1 resulted significantly
downregulated (Figures 1D–F). No significant difference in
Trem2 was detected between c-rel−/− and wt mice at this
age (Figure 1G). This expression pattern seems to indicate
a polarization of microglia/macrophages towards a particular
M2 state named M2c, that is associated with tissue repair,
as well as to debris and iron scavenging (David and Kroner,
2011), in 4-month-old c-rel−/− mice. However, the M2c
activation state was no longer detectable in 13-month-old
c-rel−/− mice. Indeed, at this age, Mrc1 and Arg1 transcripts
resulted downregulated in c-rel−/− mice when compared to
4-month-old mice, while Ym1 expression remained unchanged
(Figures 1D–F). On the other hand, we observed a significant
increase in Trem2 transcription in 13-month-old c-Rel deficient
mice when compared to younger animals (Figure 1G). Though
similar changes were found in wt mice (Figure 1G). Finally, we
did not observe biologically relevant changes in the expression
of all M2 markers between c-rel−/− and wt mice at either 13 or
18 months of age, thus suggesting a limited involvement of the
M2 polarization of microglia/macrophages in the SN of older
c-rel−/− mice.
These data support the occurrence of M2c-like pattern of
expression in the SN of c-rel−/− mice at 4 months of age, when
they do not display any sign of degeneration in this area yet.
It is followed by a mild inflammatory state characterized by Ilb
expression in 13-month-old c-rel−/− mice, when they develop a
loss of DAT immunostaining in the striatum (Lanzillotta et al.,
2015).
Immunohistochemical Characterization of
Mild Inflammatory Profile in the Substantia
Nigra of c-Rel Deficient Mice
To assess microglial activation in the premotor andmotor phases
of PD-like pathology, we analyzed the immunoreactivity for Iba1,
a constitutive marker of microglia and macrophages, in the SN
of 4-, 13- and 18-month-old c-rel−/− mice and age-matched
wt animals. Iba1 was expressed similarly, both in distribution
and morphology, in c-rel−/− and wt mice, at all the considered
ages (Figure 2). These data appeared contrasting to our previous
findings showing an increased immunoreactivity for CD11b in
the SN of 18-month-old c-rel−/− mice (Baiguera et al., 2012).
To identify the origin of the increased Mrc1
transcription in the SN of 4-month-old c-rel−/− mice,
double immunofluorescence staining with MRC1 and
Iba1 was performed in brain sections of these animals.
MRC1 immunoreactivity was not detected in Iba1-positive
parenchymal microglia, but instead in Iba1-positive cells located
at CNS interfaces (Figure 3). These non-ramified cells were
identified as non-parenchymal or CNS macrophages, namely
FIGURE 2 | Ionized calcium binding adapter molecule 1 (Iba1)
immunoreactivity in c-rel−/− and wt mice. Pictures of SN sections from 4-
(A,B), 13- (C,D) and 18-month-old animals (E,F) illustrating Iba1
immunostaining. No evident changes in microglial activation were found in
c-rel−/− mice (B,D,F) compared to age-matched wt (A,C,E).
Immunofluorescence images are representative of five sections from each
animal (n = 3 animals per group). Abbreviations: SN, substantia nigra. Scale
bar: in (A) = 100 µm for (A–F).
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FIGURE 3 | Non-parenchymal macrophages are immunoreactive to MRC1.
(A) MRC1 (red) and Iba1 (green) double-labeled cells are localized at CNS
interfaces (closed and open arrows) and not in the SN parenchyma (delimited
by the dashed line) in 4-month-old c-rel−/− mice. (B–D) Higher magnification
of MRC1-Iba1 double-labeled perivascular macrophages (closed arrow) and
Iba1-positive microglia in the SN. (E,F) Higher magnification of MRC1-Iba1
double-labeled meningeal macrophages (open arrows), and Iba1-positive
microglia, outside the SN. Upper image (A) is representative of five sections
from each animal (n = 3). Abbreviations: CNS, central nervous system;
SN, substantia nigra. Scale bars: in (A) = 100 µm; in (B) = 50 µm for (B–G).
perivascular or meningeal, depending on their localization and
morphology (Goldmann et al., 2016). Considering that the aim
of the present work was to study parenchymal microglia in
the SN, we chose not to proceed with the analysis of these few
macrophages limited to CNS borders, though it would definitely
be interesting to focus our attention on these cells in a future
study.
To establish the source of the increased Il1bmRNA in the SN
of c-rel−/−mice at 13months of age, SN sections from thesemice
were immunolabeled for IL-1β and Iba1. IL-1β expression was
mostly found in cells negative for Iba1 in 13-month-old c-rel−/−
mice (Figure 4). Considering their morphology, we speculate
these IL-1β-positive Iba1-negative cells are neurons.
The immunoreactivity for GFAP, an astrocyte marker, was
performed to analyze astrocyte activation in the SN of c-rel−/−
mice. In line with our earlier results (Baiguera et al., 2012), no
signs of astrogliosis were detected in SN sections of 18-month-
old c-rel−/− mice. Likewise, no increased reactivity to GFAP was
identified in 4- or 13-month-old c-rel−/− mice, when compared
to wt animals (Figure 5).
DISCUSSION
The present study shows that merely a mild inflammatory
process, lacking a pronounced activation of microglia and
astrocytes, anticipates SN degeneration in c-rel−/− mouse, a
FIGURE 4 | IL-1β localization in the SN. (A) Representative image of IL-1β
(red) and Iba1 (green) immunofluorescence with Hoechst (blue) staining in the
SN of 13-month-old c-rel−/− mice. Closed arrows highlight IL-1β-positive
cells. Open arrows highlight Iba1-positive cells. The image is representative of
five sections from each animal (n = 3). (B) Blank control. Abbreviations: SN,
substantia nigra. Scale bar: in (A) = 100 µm for (A,B).
novel animal model of late-onset parkinsonism (Baiguera et al.,
2012).
Although several animal models of PD have been established
in the last decades, none of them showed to develop both the
parkinsonian motor and non-motor symptoms (Cebrián et al.,
2015). Furthermore, most models display rapid dopaminergic
neuron degeneration, not replicating the slow, aging-dependent
neuronal loss characteristic of the sporadic human disease (Tieu,
2011). Recently, we have observed that, between 2 and 13
months of age, c-rel−/− mice manifest olfactory deficits and gut
dysfunctions, which are accompanied by progressive α-synuclein
accumulation in the SN and reduction of DAT immunoreactivity
in the striatum (Parrella et al., submitted). These alterations, that
are reminiscent of prodromal PD, anticipate the onset of the
motor disturbances and dopaminergic neuronal loss in the SN
that become evident at 18 months (Baiguera et al., 2012). The
aim of the present study was to investigate whether inflammation
and glial activation may be associated with or anticipate the onset
of PD-like neuropathological alterations reported in the brain of
c-rel−/− mice.
The analysis of inflammation-related transcripts in
the SN of 4-month-old c-rel−/− mice revealed increased
expression of Mrc1 and Arg1 with respect to wt mice. The
transcription of these factors was associated with a decreased
Ym1 expression, supporting the presence of the M2c-type
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FIGURE 5 | GFAP immunoreactivity in c-rel−/− and wt mice. Pictures of SN
sections from 4- (A,B), 13- (C,D) and 18-month-old (E,F) animals illustrating
GFAP astroglial immunostaining. No evident changes in astroglial activation
were found in c-rel−/− mice (B,D,F) compared to age-matched wt (A,C,E).
Immunofluorescence images are representative of five sections from each
animal (n = 3 animals per group). Abbreviations: GFAP, glial fibrillary acidic
protein; SN, substantia nigra. Scale bar: in (A) = 100 µm for (A–F).
microglial/macrophages associated with iron scavenging (David
and Kroner, 2011) in the SN of c-rel−/− mice. The M2c
microglial/macrophage polarization appeared to be transient
as it dropped down at 13 and 18 months of age. Although a
role for M2c-type microglia/macrophages in the onset and
progression of the PD-like disease has yet to be established, our
findings suggest that M2c ‘‘sentinel cells’’ in the SN of c-rel−/−
mice are indeed reacting to harmful signals already present in
brain milieu of young animals. On the contrary the loss of this
M2c-phenotype might contribute to the accumulation of iron
and likely α-synuclein in the SN of older c-rel−/− mice (Baiguera
et al., 2012).
The double labeling of MRC1 and Iba1 in the SN of these
mice allowed us to identify the MRC1-Iba1-positive cells as
non-parenchymal or CNS macrophages, rather than microglia.
This is in agreement with recently published data demonstrating
that the marker MRC1 is specific for CNS macrophages, but
not microglia, in mice (Goldmann et al., 2016) and humans
(Melief et al., 2012). It suggests that the observed changes in
the expression of Mrc1 might reflect macrophage rather than
microglial alterations.
Notably, at 13 months of age, the reduction in the expression
of M2c-specific markers was accompanied by a significant
increase of Il1b, but not Il6 or Fcgr3 transcription, which is
suggestive of a mild inflammatory profile in the c-rel−/− brain.
In wt mice, a similar increase of Il1b expression became evident
only at 18 months of age. As an augment of IL-1β is recognized to
be a feature of brain aging (Maher et al., 2004), the anticipation
of Il1b expression in c-rel−/− mice supports that c-Rel deficiency
accelerates the aging and neurodegeneration of the SN (Baiguera
et al., 2012; Lanzillotta et al., 2015). In addition, we found
that immunoreactivity for IL-1β was mostly localized within
Iba1-negative cells displaying a neuronal morphology in the SN
of c-rel−/− mice. However, we cannot exclude that other cell
types, such as microglia, might contribute to the higher level
of Il1b transcripts detected by qRT-PCR. This is in line with
previous findings showing transcription but no transduction of
IL-1β in peripheral blood mononuclear cells, as well as in the SN
of a PD mouse model (Schindler et al., 1990a,b; Depino et al.,
2003).
Anyhow, we could not detect differences in the morphology
of Iba1-positive microglia/macrophages in the SN of c-rel−/−
mice, at all the considered ages, though we previously described
the presence of activated CD11b-positive cells in the SN of 18-
month-old c-rel−/−mice (Baiguera et al., 2012). This discrepancy
may be ascribed to the use of different microglial/macrophage
markers in the two studies. Indeed, several authors reported
that CD11b and Iba1 can lead to different staining patterns
(Korzhevskii and Kirik, 2016; Lee et al., 2016; Scholtzova et al.,
2017), which depends on the microglial/macrophage activation
state (Ji et al., 2007). In particular, CD11b, although being an
unspecific marker for microglia and macrophages, as it is also
expressed inmonocytes and granulocytes (Korzhevskii andKirik,
2016), detects preferentially the activated microglial/macrophage
state. This is related to the fact that resting microglia display
low expression for membrane receptors, including CD11b,
which become upregulated upon activation (Kreutzberg, 1996).
On the other hand, Iba1 is a specific microglial/macrophage
marker, but not especially sensitive to the activated form
(Liaury et al., 2012; Korzhevskii and Kirik, 2016). Previous
evidence by Liaury et al. showed increases in immunoreactivity
for CD11b without significant difference in Iba1 in the
hippocampal dentate gyrus of Gunn rats, an animal model
of schizophrenia (Liaury et al., 2012). We can assume that
microglia may adopt a minor ‘‘intermediate’’ state of activation
detectable only by immunolabeling CD11b in c-rel−/− mice.
The Iba1-labeled microglia, by depicting microglial morphology
at all the activation states, is a realistic representation of the
mild inflammatory condition present in c-rel−/− mice. The
blunt inflammatory response is also supported by the GFAP
staining for astrocytes in SN of c-rel−/− mice. As previously
reported (Baiguera et al., 2012), c-rel−/− mice showed no
signs of astrogliosis, accordingly to findings in PD patients
(Mirza et al., 2000; Song et al., 2009; Tong et al., 2015).
The role of astrocytes in PD pathology remains controversial
(Hirsch and Hunot, 2009). Moreover, microglial activation
does not necessarily lead to the release of proinflammatory
cytokines (Depino et al., 2003). As mentioned above, it has
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been found that peripheral blood mononuclear cells, that
are able to transcribe but not translate Il1b, upon receiving
a secondary inflammatory stimulus, respond excessively by
releasing disproportionate quantities of inflammatory cytokines,
a phenomenon that is known as cell priming (Schindler et al.,
1990a,b). Therefore, we hypothesize that this ‘‘intermediate’’
microglial activation state in 18-month-old c-rel−/− mice could
belong to ‘‘primed’’ microglia. Interestingly, neurodegenerative
diseases and normal aging are responsible for microglial priming
or sensitization (Norden and Godbout, 2013). In a model of
accelerated aging, primed microglia showed an exaggerated
response to peripheral lipopolysaccharide injection (Raj et al.,
2014). Since PD patients frequently suffer from infections, being
even one of the main causes of death (Beyer et al., 2001),
it cannot be excluded that peripheral infections trigger an
excessive brain inflammatory response at the symptomatic motor
stage of the disease. Diverse factors, such as nutrition (Seidl
et al., 2014; Agim and Cannon, 2015) and physical exercise
(LaHue et al., 2016), that have been assumed to influence the
progression of PD, could very well contribute to modulate the
neuroinflammatory process (Spencer et al., 2012; Orr et al.,
2013). If we consider that c-rel−/− mice exhibit increased
susceptibility to brain aging, it would be remarkable confirming
the presence and role of primed microglia in this animal model,
by evaluating its reactivity upon a peripheral inflammatory
stimulus in further investigations. Moreover, our findings do
not clarify the origin of a putative microglial ‘‘priming’’ and
whether c-rel−/− mice display an impaired neuronal resilience at
12 months of age, as suggested by the increased Il1b expression
in SN and loss of DAT in the striatum (Lanzillotta et al.,
2015).
Definitely, whether and how inflammation contributes to
PD pathology is still debated. Post-mortem analysis of PD
brains has shown reactive microglia in the SN of patients at the
end stage of the disease (McGeer et al., 1988; Imamura et al.,
2003). The assessment of microglial activation in vivo at earlier
stages of PD can be achieved by positron emission tomography
(PET) imaging of radioligand binding to mitochondrial
translocator protein 18 kDa (TSPO), a molecule expressed
during microglial activation (Banati et al., 1997). However,
genetic polymorphisms in TSPO cause an elevated variability in
binding affinity, which is the main limitation of this technique
(Owen et al., 2012; Yoder et al., 2013). In two studies that
have controlled for TSPO rs6791 polymorphism, no differences
were seen in [18F]-FEPPA binding in PD patients compared
to controls (Koshimori et al., 2015; Ghadery et al., 2017).
Thus, whilst microglial activation seems to be a pathological
hallmark of end-stage PD, small-scale studies on the activation of
microglia in patients at initial phases of the disease suggest there
is no association of microgliosis with early disease progression.
These findings are also supported by recent investigations
showing no difference in CSF cytokine content in patients
with mild PD (Shi et al., 2011; Lindqvist et al., 2013). By rising
some concerns about the role of inflammation as a trigger of
the disease, this scenario deserves confirmation in large-scale
studies.
In conclusion, our findings hint that severe inflammation, and
particularly microglial pro-inflammatory activation, is not a key
hallmark of PD-like phenotype in c-Rel deficient mice. So far,
we have analyzed microglial activation in mice up to 18 months
of age, when dopaminergic neuronal loss in the SN is about
40% (Baiguera et al., 2012). The moderate amount of neuronal
degeneration leads us to speculate that, at this age, c-rel−/− mice
are modeling a mild PD. Thus, we cannot exclude that c-rel−/−
mice may develop strong microgliosis at older ages, similar to
what is found in post mortem brains of late-stage PD subjects
(McGeer et al., 1988; Imamura et al., 2003). These findings own
potentially relevant implications for understanding the role of
neuroinflammation in PD.
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